ATLANTA, GA – – (Globe Newswire – November 18, 2025) – – A shareholder class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or the “Company”) (NASDAQ: SKYE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose key facts, including allegations that:   (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

If you purchased shares of Skye between November 4, 2024 and October 3, 2025,  and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/sky-bioscience/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is January 16, 2026.